Abstract
Malignant pleural effusion (MPE) is a common complication of many tumor types, arising at the onset of terminal cancer with a median survival of 3-12 months. Herein, we have characterized and evaluated the activity of thiostrepton (TS) on malignant and immune cell types present in MPE from patients diagnosed with primary lung, breast, prostate, pancreatic and ovarian cancers. TS targets mitochondrial peroxiredoxin 3 (PRX3) and disrupts redox homeostasis preferentially in malignant tissues, presenting a promising therapeutic approach currently under investigation in the MITOPE clinical trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
